Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail

It seems that Illumina (NASDAQ: ILMN) is making a push into the cancer diagnostics space. According to an article published Wednesday by Reuters citing "people familiar with the matter," the gene-sequencing specialist is in discussions to purchase Grail -- an early-stage company active in the segment.

While privately held, Grail would make a pricey target. According to Reuters' sources, after several funding rounds, it's valued at around $6 billion.

Image source: Getty Images.

Continue reading

Source Fool.com